This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is AmerisourceBergen (ABC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
Should Value Investors Buy Laboratory Corp. of America (LH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson's (MCK) Latest Launch to Give Access to OTC Products
by Zacks Equity Research
McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.
McKesson (MCK) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $414.09, marking a -0.4% move from the previous day.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $391.25, marking a -1.45% move from the previous day.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
McKesson (MCK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $389.22 in the latest trading session, marking a +1.2% move from the prior day.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
McKesson (MCK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.42% and 1.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's How Inter Parfums (IPAR) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
Inter Parfums' (IPAR) Q1 earnings are expected to reflect gains from robust top-line growth, strength across brands, expansions and product launches.
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Staar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.
SmileDirectClub (SDC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AmerisourceBergen (ABC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 6.38% and 4.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?